Ismail Kirrout
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ismail Kirrout has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Aiman S. Sarsenbaeva
Department of Gastroenterology Chelyabinsk Regional Clinical Hospital Chelyabinsk Russia
1 shared publication- Alfredo J. Lucendo
Department of Gastroenterology Hospital General de Tomelloso Tomelloso Spain
1 shared publication - Angeles Perez Aisa
Department of Gastroenterology Hospital Universitario Costa del Sol, RICAPPS–Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de la Salud Marbella Spain
1 shared publication - Antonietta Gerarda Gravina
Department of Precision Medicine, Hepatogastroenterology and Digestive Endoscopy Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy
1 shared publication - Antonio Gasbarrini
Department of Internal Medicine and Gastroenterology Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore Rome Italy
1 shared publication - Antonio Moreno Loro
Department of Gastroenterology Hospital Universitario Virgen del Rocío Sevilla Spain
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Helicobacter
- Vol. 31 (6)
Lack of Usefulness of Literature‐Based Helicobacter pylori Resistance Data for Predicting First‐Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp‐ EuReg )
Background: Helicobacter pylori ( H. pylori ) infection causes gastritis, peptic ulcer disease, and gastric cancer. Without an effective vaccine, eradication therapy remains crucial. However, increasing antibiotic resistance compromises treatment effectiveness. Objective: To evaluate whether literature‐based resistance data could predict first‐line empirical treatment effectiveness. Methods: Resistance rates for clarithromycin, metronidazole, and levofloxacin were extracted from bibliographic reviews and estimated for three timeframes: the treatment year, the preceding year, and the last five years average. These rates (2008–2024) were matched with outcomes from the European Registry on H. pylori Management (Hp‐EuReg, WorldHpReg partner), a prospective real‐world study involving 40 countries. Analyses included Spearman's correlations, multivariate logistic regressions adjusted for demographic, clinical, and therapeutic‐related variables, bootstrap resampling stratified by eradication success, and Random Forest models. Results: Analysis included 37,659 patients receiving first‐line empirical treatment from 13 countries. Moderate negative correlations were observed between metronidazole and clarithromycin resistances for some regimens. In the regression model, including either contemporaneous or previous‐year resistance rates, clarithromycin resistance showed a negligible positive association, while metronidazole resistance was negatively associated. In regimen‐specific models, previous‐year clarithromycin resistance was positively associated with success in concomitant therapy, whereas higher five‐year mean clarithromycin resistance reduced eradication odds in quadruple clarithromycin–amoxicillin–bismuth therapy. Random Forest models identified compliance, proton‐pump inhibitor dose, regimen duration, and treatment as the strongest predictors of eradication, while resistance variables contributed minimally. Conclusion: Literature‐based resistance data are not useful for guiding real‐world first‐line H. pylori therapy, highlighting the need for individualized antibiotic susceptibility testing to obtain reliable resistance information. Trial Registration: ClinicalTrials.gov identifier: NCT02328131
- 5 November 2026
- Published by Wiley in Helicobacter
- Vol. 31 (6)
Open AccessLack of Usefulness of Literature‐Based Helicobacter pylori Resistance Data for Predicting First‐Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp‐ EuReg )
Background: Helicobacter pylori ( H. pylori ) infection causes gastritis, peptic ulcer disease, and gastric cancer. Without an effective vaccine, eradication therapy remains crucial. However, increasing antibiotic resistance compromises treatment effectiveness. Objective: To evaluate whether literature‐based resistance data could predict first‐line empirical treatment effectiveness. Methods: Resistance rates for clarithromycin, metronidazole, and levofloxacin were extracted from bibliographic reviews and estimated for three timeframes: the treatment year, the preceding year, and the last five years average. These rates (2008–2024) were matched with outcomes from the European Registry on H. pylori Management (Hp‐EuReg, WorldHpReg partner), a prospective real‐world study involving 40 countries. Analyses included Spearman's correlations, multivariate logistic regressions adjusted for demographic, clinical, and therapeutic‐related variables, bootstrap resampling stratified by eradication success, and Random Forest models. Results: Analysis included 37,659 patients receiving first‐line empirical treatment from 13 countries. Moderate negative correlations were observed between metronidazole and clarithromycin resistances for some regimens. In the regression model, including either contemporaneous or previous‐year resistance rates, clarithromycin resistance showed a negligible positive association, while metronidazole resistance was negatively associated. In regimen‐specific models, previous‐year clarithromycin resistance was positively associated with success in concomitant therapy, whereas higher five‐year mean clarithromycin resistance reduced eradication odds in quadruple clarithromycin–amoxicillin–bismuth therapy. Random Forest models identified compliance, proton‐pump inhibitor dose, regimen duration, and treatment as the strongest predictors of eradication, while resistance variables contributed minimally. Conclusion: Literature‐based resistance data are not useful for guiding real‐world first‐line H. pylori therapy, highlighting the need for individualized antibiotic susceptibility testing to obtain reliable resistance information. Trial Registration: ClinicalTrials.gov identifier: NCT02328131